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Evaluating the p&infarction patient before hospital dis. 
charge. If my father had a heart atta.P& what test or combi- 
nation of tests would I want done as part of his postinfarction 
evaluation? Without question. I hope that he would agree to 
undergo coronary angiography and left ventriculography. 
That is easy for me to say because my father. who has never 
smoked and is about 80 years old. has a normal blood 
preswe and serum cholesterol level. Good news for him. 
and coed news for me. However, in this issue of the 
Jo&al, Candell-Rieraet al. (1) reasonably conclude that the 
roost effective noninvasive strategy for the postinfarction 
patient is a simple exercise test and a two-dimensional 
echocardiogram. There have been numerous reports (Z-5) on 
prognosticition for the survivor of a myocardial infarction 
and various clinical, noninvasive and invas& strategies 
have been shown to be useful in this regard. However. 
invasive cardiologists still favor their (oar) methods. those 
with a nuclear or echocardiographic bent use their favorites 
and various third party payers encourage the least costly 
approach. Only submaximal stress resting. which reassures 
the patient before hospital discharge and helps with the 
exercise prescription. is widely accepted and used. even 
though iti predictive value h&not bken unquestioned (6). 
Exercise-provoked ischemia may be difficult to identify in 
the postinfarction patient. Rcsulls of exercise thallium-201 
scintigraphy were negative in nearly 50% of the patients 
treated with recombinant tissue-type plasminogen activator 
in one recent series (7). Of concern are the characteristics 
of this potentially overlooked group of pzdients because 
they may be relatively young and have anatomic character- 
istxcs associated with a high risk of future events durine. 
follow-up (in lhat series 171. 47% hzd an anterior wall 
infarction and 39% had documented multivessel disease). 
The conclusions do confirm what others (7-9) have sug- 
gested regarding the bmited additional clinical usefulness of 
expensive concomitant radionuclide imaging. except in we- 
cilic circumstances. 
The present study. Foor of five patieets with acute myo 
cardial infarction survive to hospital discharge and perhaps 
an even higher proportion will do so with the more wide- 
spread availability and use of thrombolytic therapy l10.11). 
With thousands of patients surviving infarction, which 
is frequently their mitial cardiac event, it is imperative that 
we do not miss this opportunity to prevent future rehospi- 
talirations. cardiac events and oremature death. Event rates 
after acute myocardial infarct& vary from series to series, 
but even in the study by Candell-Riera et al. (I) of “low 
risk” patients with a first infarction, there was a MIA 
complication rate in the 1st year of follow-up after hospital 
discharge. 
The studv samole reflects information from <5!l% of the 
patients with inft&?n seen at the investigators’ hospital 
and these patients constituted a relatively low risk group of 
young patients with a first and uncomplicated infarction. 
Furtherowe. the overwhelming majority were not treated 
with a thrombolvtic agent. This factor alone may have 
importwtt ramilic&nrbecause the changing characteristics 
of these wvivors may well change their future event rates 
(12). Of the study patients, 36% had multivessel disease and 
27% had three-vessel disease according to the investigators’ 
definition of a 70% reduction in lumen diameter as signifi- 
cant. The Veterans Administration (13) and European Co- 
operative (141 studies used a 50% reduction in lumen diam- 
eter as the entry criterion and improved survival was shown 
in those patients with multivessel disease. With use of this 
definition. one could expect about 45% ofthe patients in the 
study of Candell-Riera et al. (I) to have multivessel disease. 
and >33% to have three-vessel disease (IS). Follow-up WBE 
limited to I year, not 5 years as in these longer trials, and 
continued cr&ver to s&cal therapy shottli be expected. 
despite the inevitable need for invasive study and the occur- 
rence of additional cardiac events in a significant number of 
patients. 
Clinieal elw to increased risk. General clinical clues that 
point to a significant increase in risk of events after myocar- 
dial infarction include a history of orevious myocardial 
infarction. recurrent myocardial &hernia after hospitaliza- 
tion, congestive heart failure and the presence ofcomplex or 
frequent ventricular arrhythmias (16). About 50% of all 
patients wilh infarction will have one or more of these 
problems. Is this not enough to suggest that the earliest 
possible delineation of coronary anatomy is imperative so 
that more definitive thempy can be addressed and planned if 
necessary, thereby avoiding future setbacks such as rehos- 
pitalin.tion for angina. recurrent infarction and the associ- 
ated medical costs? 
Should we continue to spend money for expensive non- 
invasive tests aimed at selecting most. but not all. high risk 
patients and identifying most, but not all. low risk pattents 
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